Merck Common Stock Net 2010-2024 | MRK

Merck common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
  • Merck common stock net for the quarter ending September 30, 2024 was $1.788B, a 0% increase year-over-year.
  • Merck common stock net for 2023 was $1.788B, a 0% decline from 2022.
  • Merck common stock net for 2022 was $1.788B, a 0% decline from 2021.
  • Merck common stock net for 2021 was $1.788B, a 0% decline from 2020.
Merck Annual Common Stock Net
(Millions of US $)
2023 $1,788
2022 $1,788
2021 $1,788
2020 $1,788
2019 $1,788
2018 $1,788
2017 $1,788
2016 $1,788
2015 $1,788
2014 $1,788
2013 $1,788
2012 $1,788
2011 $1,788
2010 $1,788
2009 $1,781
Merck Quarterly Common Stock Net
(Millions of US $)
2024-09-30 $1,788
2024-06-30 $1,788
2024-03-31 $1,788
2023-12-31 $1,788
2023-09-30 $1,788
2023-06-30 $1,788
2023-03-31 $1,788
2022-12-31 $1,788
2022-09-30 $1,788
2022-06-30 $1,788
2022-03-31 $1,788
2021-12-31 $1,788
2021-09-30 $1,788
2021-06-30 $1,788
2021-03-31 $1,788
2020-12-31 $1,788
2020-09-30 $1,788
2020-06-30 $1,788
2020-03-31 $1,788
2019-12-31 $1,788
2019-09-30 $1,788
2019-06-30 $1,788
2019-03-31 $1,788
2018-12-31 $1,788
2018-09-30 $1,788
2018-06-30 $1,788
2018-03-31 $1,788
2017-12-31 $1,788
2017-09-30 $1,788
2017-06-30 $1,788
2017-03-31 $1,788
2016-12-31 $1,788
2016-09-30 $1,788
2016-06-30 $1,788
2016-03-31 $1,788
2015-12-31 $1,788
2015-09-30 $1,788
2015-06-30 $1,788
2015-03-31 $1,788
2014-12-31 $1,788
2014-09-30 $1,788
2014-06-30 $1,788
2014-03-31 $1,788
2013-12-31 $1,788
2013-09-30 $1,788
2013-06-30 $1,788
2013-03-31 $1,788
2012-12-31 $1,788
2012-09-30 $1,788
2012-06-30 $1,788
2012-03-31 $1,788
2011-12-31 $1,788
2011-09-30 $1,788
2011-06-30 $1,788
2011-03-31 $1,788
2010-12-31 $1,788
2010-09-30 $1,789
2010-06-30 $1,787
2010-03-31 $1,786
2009-12-31 $1,781
2009-09-30 $30
2009-06-30 $30
2009-03-31 $30
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $260.350B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51